Journal of Scleroderma and Related Disorders

Scope & Guideline

Connecting the dots in scleroderma research for better patient outcomes.

Introduction

Welcome to the Journal of Scleroderma and Related Disorders information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Journal of Scleroderma and Related Disorders, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2397-1983
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
CountryItaly
TypeJournal
Convergefrom 2016 to 2024
AbbreviationJ SCLERODERMA RELAT / J. Scleroderma Relat. Disord.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The Journal of Scleroderma and Related Disorders focuses on advancing the understanding and management of systemic sclerosis and related conditions. It serves as a platform for innovative research that spans a wide array of clinical, epidemiological, and therapeutic aspects of scleroderma.
  1. Clinical Research on Systemic Sclerosis:
    The journal prioritizes original clinical studies that investigate various manifestations of systemic sclerosis, including its impact on organs such as the lungs, heart, and gastrointestinal tract.
  2. Therapeutic Approaches and Innovations:
    Research articles often explore novel therapeutic strategies and treatment protocols, including the use of biologics, immunosuppressants, and emerging therapies tailored to scleroderma.
  3. Patient-Centered Care and Quality of Life:
    The journal emphasizes studies that assess the quality of life and patient-reported outcomes for individuals with systemic sclerosis, highlighting the importance of psychosocial factors in disease management.
  4. Epidemiological and Public Health Studies:
    There is a consistent focus on epidemiological research that addresses the prevalence, risk factors, and long-term outcomes associated with systemic sclerosis across diverse populations.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that brings together insights from various fields such as rheumatology, dermatology, cardiology, and nutrition to provide a holistic understanding of systemic sclerosis.
Recent publications in the Journal of Scleroderma and Related Disorders indicate several emerging themes that reflect the evolving landscape of research in systemic sclerosis. These trends highlight areas of growing interest and potential impact on clinical practice.
  1. Impact of COVID-19 on Systemic Sclerosis:
    An increasing number of studies address the implications of COVID-19 on the management and outcomes of patients with systemic sclerosis, emphasizing the need for adaptive care strategies during the pandemic.
  2. Nutrition and Lifestyle Interventions:
    There is a rising focus on the role of nutrition and lifestyle factors in the management of systemic sclerosis, exploring how these elements can influence disease progression and patient well-being.
  3. Digital Health and Telemedicine:
    Emerging research is examining the use of digital health technologies and telemedicine in the management of systemic sclerosis, particularly in enhancing patient access to care and improving monitoring.
  4. Mental Health and Psychosocial Factors:
    Studies increasingly explore the psychosocial dimensions of living with systemic sclerosis, including the effects of mental health on disease management and quality of life.
  5. Machine Learning and Diagnostic Innovations:
    There is a growing interest in the application of machine learning and other advanced technologies to improve the diagnosis and management of systemic sclerosis, reflecting broader trends in healthcare innovation.

Declining or Waning

While the Journal of Scleroderma and Related Disorders continues to expand its focus, certain themes appear to be declining in prominence. This trend may reflect shifts in research priorities or advancements in understanding that have influenced the scope of inquiry.
  1. Rare and Uncommon Manifestations:
    Research focusing on rare manifestations of systemic sclerosis, such as specific types of skin involvement or rare comorbidities, has decreased. This may indicate a shift towards more prevalent and impactful aspects of the disease.
  2. Historical Perspectives and Case Reports:
    There has been a noticeable reduction in the publication of historical case reports and vignettes, suggesting a possible move towards more data-driven, clinical, and experimental research.
  3. Basic Science Research:
    The journal has seen a waning interest in basic science studies that do not directly translate to clinical implications, possibly due to a growing emphasis on translational research that bridges bench to bedside.

Similar Journals

LUPUS

Elevating knowledge in lupus through impactful research.
Publisher: SAGE PUBLICATIONS LTDISSN: 0961-2033Frequency: 14 issues/year

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Bridging Research and Practice in Dermatology
Publisher: ADIS INT LTDISSN: 1175-0561Frequency: 6 issues/year

The American Journal of Clinical Dermatology, published by Adis International Ltd, is a leading peer-reviewed journal dedicated to advancing the field of dermatology. With a notable impact factor and a prestigious Q1 rank in both Dermatology and Miscellaneous Medicine categories, this journal stands out as a valuable resource for researchers and clinicians alike, offering cutting-edge insights into clinical practice and innovative treatment strategies. Its comprehensive scope encompasses a broad range of topics within dermatology, addressing both common and rare conditions, with a focus on emerging therapies and technologies. As it converges its publication years from 2000 to 2024, the journal remains an essential platform for disseminating high-quality research to professionals striving to improve patient care and outcomes. With the ISSN 1175-0561 and E-ISSN 1179-1888, the American Journal of Clinical Dermatology facilitates greater accessibility to pivotal findings within the field, making it an indispensable resource for anyone involved in dermatological research and practice.

RHEUMATOLOGY INTERNATIONAL

Unraveling the complexities of immunology and rheumatology.
Publisher: SPRINGER HEIDELBERGISSN: 0172-8172Frequency: 12 issues/year

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Therapeutic Advances in Neurological Disorders

Empowering progress in neurological science and practice.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Multiple Sclerosis International

Advancing knowledge, transforming lives in MS research.
Publisher: HINDAWI LTDISSN: 2090-2654Frequency:

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

LANCET NEUROLOGY

Elevating Knowledge in Neurology
Publisher: ELSEVIER SCIENCE INCISSN: 1474-4422Frequency: 12 issues/year

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

ACTA NEUROLOGICA SCANDINAVICA

Innovating Understanding of Neurological Disorders
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Reumatologia Clinica

Pioneering the path to innovative rheumatology treatments.
Publisher: ELSEVIER ESPANA SLUISSN: 1699-258XFrequency: 6 issues/year

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

JOURNAL OF CLINICAL PERIODONTOLOGY

Exploring the Frontiers of Periodontal Knowledge
Publisher: WILEYISSN: 0303-6979Frequency: 12 issues/year

JOURNAL OF CLINICAL PERIODONTOLOGY, published by Wiley, is a leading academic journal dedicated to advancing the understanding and practice of periodontology. Since its inception in 1974, the journal has carved a niche in the field, achieving a remarkable Q1 ranking in Periodontics and securing a commendable Scopus rank of #2 out of 24 in Dentistry, placing it within the 93rd percentile of its category. With a robust commitment to publishing rigorous research, clinical studies, and comprehensive reviews, the journal provides an essential platform for researchers, dental professionals, and students to disseminate knowledge and keep abreast of the latest advancements in periodontal science. Although the journal is not open access, it remains highly influential in shaping the practices that underpin effective patient care and improving oral health globally. The journal's address in Hoboken, New Jersey, belies its international reach and the diverse contributions it attracts from around the world, ensuring its relevance and prestige in the rapidly evolving landscape of clinical periodontology.

International Journal of Rheumatology

Transforming the landscape of rheumatological care.
Publisher: HINDAWI LTDISSN: 1687-9260Frequency: 1 issue/year

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.